Söndag 20 April | 10:19:19 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-27 N/A Bokslutskommuniké 2025
2025-08-21 07:30 Kvartalsrapport 2025-Q2
2025-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2025-04-03 - Årsstämma
2025-02-28 - Bokslutskommuniké 2024
2024-08-23 - Kvartalsrapport 2024-Q2
2024-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-01 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
2025-04-03 16:17:00

Following Gubra’s Annual General Meeting 2025 taking place earlier today we are pleased to confirm some exciting changes to the Board welcoming new perspectives to support the journey ahead.

As recommended by the Nomination Committee, the following members were re-elected to the Board:

  • Jacob Jelsing
  • Monika Lessl
  • Alexander Thomas Martensen-Larsen
  • Astrid Haug
  • Arndt Justus Georg Schottelius

Henriette Dræbye Rosenquist did not stand for re-election. The Board extends heartfelt thanks to Henriette for her significant contributions wishing her all the best in her new endeavours.

Welcoming new and old faces
The Board welcomes Gubra Co-Founder and Scientific Advisor Niels Vrang’s re-entry to the board and Claudia Mitchell as new members of the Board. Their collective experience in biotech innovation, research, and entrepreneurship will be a valuable asset to the next chapters in the company’s growth journey.

A new Chair at the helm
Monika Lessl, previously serving as a Board member, has been appointed as the new Chair, succeeding Jacob Jelsing, who remains an active member of the Board. As internationally experienced pharma and life science executive with more than 25 years of R&D and Innovation leadership, Monika brings visionary leadership and deep insight into innovation and sustainability - two key pillars of Gubra’s mission.

Quote from incoming Chair, Monika Lessl:

“I am honoured and excited to take over the chair at Gubra and look forward to supporting Gubra's impressive growth journey and taking it to the next level. The strength of the people at Gubra, the deep commitment to science, and the technological capabilities are truly exceptional. This will remain the foundation as well as the commitment to society by contributing to a healthy planet.”

With a refreshed Board and continued commitment to scientific excellence and sustainability, Gubra is well-positioned for the next chapter in its growth journey.

Learn more about the AGM agenda and get to know the Board of Directors through their CVs here: Notice to convene Annual General Meeting 2025